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Abstract
Background: Limitations in our current knowledge of normative physiologic changes in thyroid function during
the periconception window narrow our ability to establish an optimal approach to screening and diagnosis of
thyroid disease in pregnant women. The objective of this study was to characterize changes in thyroid function
during the transition from the pre-pregnant to pregnant state in normal fertile women.
Methods: Women (N = 60) ages 30-42 years without a history of thyroid disease, who were planning pregnancy,
were observed prospectively before and during early pregnancy. Thyroid function (thyroid stimulating hormone,
TSH and free thyroxine, FT4) was measured before conception and between 6 and 9 weeks gestation. Pre-
pregnancy samples were analyzed for thyroid antibodies. Bivariate analyses and longitudinal curves (general
estimating equation models) were used to analyze changes in thyroid function during the periconception window
by antibody status.
Results: Pre-pregnancy TSH values were significantly higher than early pregnancy TSH (p < 0.001), but FT4 values
did not differ (p = 0.53). TSH declined as gestational age increased (P < 0.01). Thyroid antibody positive women
had a higher pre-pregnancy TSH compared to antibody negative women (p < 0.01). Periconceptional change in
thyroid function was more variable among women with antibodies (p < 0.001). 50% of women with elevated pre-
pregnancy TSH values (TSH > 3.0 mIU/L) had normal TSH values (TSH < 2.5 mIU/L) in pregnancy.
Conclusions: TSH values decline during the transition from pre-pregnancy to early pregnancy. The change in TSH
appears to be less predictable in women with thyroid antibodies. Periconceptional changes in thyroid function
should be considered in formulating prenatal thyroid screening guidelines.
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Background
Reproductive hormones have been shown to impact
thyroid physiology during pregnancy [1-3]. Estrogens sti-
mulate thyroid binding globulin (TBG) production by
the liver effectively decreasing free thyroxine (FT4) [1].
Human chorionic gonadotropin binds to and activates
the thyroid stimulating hormone (TSH) receptor [2,3].
Therefore, high levels of reproductive hormones pro-
duced during pregnancy likely lead to alterations in
maternal thyroid function and measures of thyroid func-
tion (TSH and FT4 levels). Normal maternal thyroid
function during the periconception window defined as
the transition from pre-pregnancy through the early first
trimester is important as: 1) implantation disorders may
predispose to adverse obstetrical outcomes [4,5], 2)
most miscarriages occur during this interval [6,7], and
3) normal early fetal neurological development requires
maternal thyroxine [8].
Currently, normative data defining thyroid function
during early pregnancy derives primarily from cross-sec-
tional population-based studies of pregnant women
[9-11]. Use of cross-sectional data assumes 1) pregnancy
induced changes in thyroid function are the same for all
women, 2) women with normal pre-pregnancy thyroid
levels will have normal pregnancy thyroid levels, and 3)
values outside of 95% confidence limits for the popula-
tion represent thyroid dysfunction. Longitudinal data
relating to changes in thyroid function surrounding the
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time of conception are limited to studies in women with
thyroid disease or infertility and cannot be extrapolated
to a general population of healthy, fertile women
[1,12,13].
Gaps in our current knowledge of normal physiologic
changes in thyroid function during the periconception
window limit our ability to establish effective methods
for pre-conception screening and treatment and hamper
efforts to identify potential “at risk” populations that
may benefit from early intervention. We conducted a
prospective observational study aimed at characterizing
the periconception changes in thyroid function in nor-
mal fertile women with and without thyroid antibodies.
We analyzed data derived from blood samples obtained
before conception and during early viable pregnancies in
a group of women who conceived without medical assis-
tance in less than 6 months.
Methods
Study design
This prospective observational study included 60 women
between the ages of 30 and 44 years. All subjects were
participants in Time to Conceive (TTC), an on-going
study approved by the Institutional Review Board at the
University of North Carolina at Chapel Hill [14]. TTC
enrolls women 30-44 years of age with proven or
untested fertility who have been actively attempting
pregnancy for less than 3 months. A blood sample is
obtained during the early follicular phase in the first
menstrual cycle after enrollment and sera are stored at
-80°C. In those who conceive, transvaginal ultrasonogra-
phy is performed between 6 and 9 weeks gestation
(based on last menstrual period). TTC study participants
reporting no history of thyroid disease who conceived
viable pregnancies between January 2009 and April 2010
were recruited to participate in this study; written con-
sent was obtained during the scheduled visit for ultraso-
nography. The early pregnancy blood sample was
obtained at the time of the viability ultrasound.
Blood samples obtained before and during early preg-
nancy were processed in the same fashion. Ultrasono-
graphy was performed by one of the two authors using
standard technique and a vaginal probe (5 MHz). Gesta-
tional age was defined by the crown-rump length
obtained during the ultrasound.
Thyroid hormone assays
Pre-pregnancy samples were analyzed for thyroperoxi-
dase (TPO) and thyroglobulin (TG) antibodies, TSH,
and free thyroxine (FT4); those obtained during preg-
nancy were analyzed only for TSH and FT4. Serum
samples were shipped on dry ice via overnight carrier to
the University of Southern California Endocrinology
Laboratories and all samples were analyzed at the same
time. Serum TSH and FT4 were measured using a third
generation electrochemiluminescent immunoassay
(Roche Elecsys 2010 Analyzer); reference values were
0.30-3.0 mIU/liter for TSH and 0.80-2.00 ng/dL for FT4.
The intra- and interassay variation coefficients were
4.0% and 3.6% for TSH and 2.4% and 4.0% for FT4.
TPO and TG antibodies were measured using a radio-
immunoassay kit (Kronus, Star, ID) with values greater
than 1.0 U/mL considered positive; the intra- and inter-
assay coefficients of variation were less than 9% for both
assays.
Statistical analysis
Descriptive statistics were calculated for TSH and FT4
for all subjects at baseline (preconception) and during
early pregnancy (6-9 weeks gestation, based on crown-
rump length) and in subjects with and without thyroid
antibodies (TPO or TG). TSH was not normally distrib-
uted. For statistical analyses, TSH values were natural
log (ln)-transformed to achieve normalcy and accommo-
date for outliers. Groups were compared using the stu-
dent t-test. Preconception and pregnancy hormone
levels were compared using a paired t-test. Geometric
means are presented for TSH for comparison of groups.
One sample test of proportion was used to compare the
prevalence of thyroid antibody positive women to the
prevalence in the general population.
To compare changes in hormone levels over the peri-
conception window by presence of thyroid antibodies
general estimating equation (GEE) models were created.
These models allow one to analyze changes in TSH con-
centrations in subjects with and without thyroid antibo-
dies, using a variable for gestational age (preconception
set as 0) to analyze the independent effect of gestational
age on TSH levels, using a variable for antibody status
to analyze the independent effect of thyroid antibodies
on TSH levels, and using an interaction term defined by
the product of gestational age and antibody status to
compare the pattern of change (or shape of the hor-
mone curve) by antibody status. GEE models allow for
analysis of data with repeated measurements on the
same subject over time, differing from repeated measure
analysis of variance (MANOVA) in that the method
does not require an equal number of measurements and
equal time spacing. Similar analyses were conducted
with FT4. All analyses were conducted using STATA
11.0 (College Station, TX).
Results
The median age of subjects was 33 years (range 30-43
years); 44/60 (73%) were under age 35; 51 (86%) were
White, 4 (6%) Black, 4 (6%) Asian, and 1 (2%) had
mixed race/ethnicity (Table 1). The median preconcep-
tion TSH was 2.0 mIU/L (Interquartile range (IQR) 1.3-
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2.45) and the corresponding FT4 was 1.22 ng/dL (IQR
1.15-1.26). The median gestational age at time of early
pregnancy ultrasound was 7.4 weeks gestation (IQR 7.0-
7.7). All pregnancies were singletons and were achieved
in less than 6 menstrual cycles.
In the study cohort, the early pregnancy TSH values
were significantly lower than the preconception TSH
values (geometric mean ± standard deviation (SD): 1.45
± 2.2 vs. 1.9 ± 1.9 mIU/L, p < 0.001). The pattern of
change in median TSH levels across the periconcep-
tional interval and early pregnancy (< 10 weeks) is
illustrated in Figure 1. TSH values before pregnancy and
at 6 weeks gestation were similar. After 6 weeks gesta-
tion, TSH values declined significantly as gestational age
increased (Pgestational age < 0.01). FT4 levels remained
unchanged over the periconception window (mean ±
SD: pre-pregnancy 1.22 ± 0.18 vs. pregnancy 1.23 ± 0.16
ng/dL, p = 0.5).
Sixteen of the 60 subjects (26.6%) had detectable thyr-
oid antibodies; 10 (17%) had TPO antibodies, 13 (22%)
had TG antibodies, and 7 (12%) had both. The precon-
ception TSH levels were significantly higher in women
Table 1 Characteristics of the study population
All women Antibody positive women Antibody negative women TSH ≥ 3.0 mIU/liter
Subjects 60 16 44 8
Age (years)a 33 (30-34) 31.5 (30-33) 33 (31-36) 30.5 (30-32)
Ethnicity
White 52 (86%) 13 (81%) 39 (89%) 7 (88%)
African American 4 (6%) 2 (13%) 2 (5%) 1 (12%)
Asian 4 (6%) 0 (0%) 4 (9%) 0 (0%)
Other 1 (2%) 1 (6%) 0 (0%) 0 (0%)
Preconception TSH (mIU/L)b 1.9 ± 1.9 2.68 ± 2.13 1.63 ± 1.67 3.78 ± 1.24
Preconception Free T4 (ng/dL)c 1.22 ± 0.18 1.18 ± 0.16 1.23 ± 0.18 1.18 ± 0.20
Gestational Agea (weeks) 7.4 (7.0-7.7) 7.3 (6.9-7.6) 7.4 (7.1-7.9) 6.6 (6.4-7.6)
Early pregnancy TSH b (mIU/L) 1.45 ± 2.2 2.13 ± 2.96 1.26 ± 2.00 2.79 ± 1.56
Early pregnancy Free T4 (ng/dL)c 1.23 ± 0.16 1.20 ± 0.16 1.24 ± 0.16 1.22 ± 0.09
a Median (Interquartile range)
b Geometric mean ± standard deviation
c Mean ± standard deviation
Figure 1 Periconception changes in TSH. Median (with interquartile range) serum TSH concentrations (mIU/L) are shown in the 60 study
participants across the preconception and early pregnancy time frame defined by our study (< 10 weeks). Pre-pregnancy values are presented
at 0 weeks gestation.
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with antibodies than in those without antibodies (geo-
metric mean ± SD 2.68 ± 2.13 vs. 1.63 ± 1.67 mIU/L, p
= 0.005); pre-pregnancy FT4 values were not different
(Table 1). An analysis of the change in TSH levels dur-
ing periconception by presence of antibodies revealed
that TSH levels in women with antibodies were signifi-
cantly higher than in those without antibodies (Pantibody
presence < 0.001); the overall pattern of change was simi-
lar in the two groups (Pantibody presence * gestational age =
0.96).
The mean change in TSH from preconception to early
pregnancy was -0.40 mIU/L (range -7.2 to 2.4). Mean
change in TSH did not statistically differ by antibody
status (antibody positive group -0.65 ± 2.2 mIU/L; anti-
body negative group -0.31 ± 0.60 mIU/L, p = 0.36);
however, the change in TSH was more variable among
women with antibodies (variance ratio test, P < 0.001).
We further analyzed our data in the subset of eight
subjects (13%) having a preconception TSH concentra-
tion greater than 3.0 mIU/L (> 2 SD above the mean
established in the laboratory), all having a normal pre-
pregnancy FT4 levels (Table 1). In this subgroup, pre-
conception TSH values were again significantly higher
than TSH values observed during early pregnancy (geo-
metric mean ± SD 3.78 ± 1.24 vs. 2.79 ± 1.56 mIU/L, p
< 0.001); 4/8 (50%) had a normal early pregnancy TSH
concentration (< 2.5 mIU/L).
Discussion
Our unique longitudinal design allowed us to examine
periconception changes in thyroid function within a
group of women with no known history of thyroid dis-
ease or infertility. Longitudinal data confirmed previous
cross-sectional data that implied that a woman’s TSH
values would decline from pre-pregnancy to early preg-
nancy. TSH started to decline after 6 weeks gestation.
Presence of thyroid antibodies was associated with
higher pre-pregnancy and early pregnancy TSH values.
While absolute change in TSH did not differ signifi-
cantly between women with and without thyroid antibo-
dies, change in TSH was more variable among women
with antibodies. Fifty percent of women with abnormal
pre-pregnancy TSH values had TSH values within the
normal range in early pregnancy.
Our results are consistent with those of previous large
population-based studies observing that TSH levels
decline gradually as the concentration of HCG increases
during early pregnancy [9,10]. While these studies
described women following the detection of pregnancy,
our study focuses on the transition from the non-preg-
nant to pregnant state. Although FT4 concentrations
during the periconceptional interval were unchanged,
TSH is arguably the more sensitive and accurate mea-
sure of the tissue levels and activity of thyroxine.
Our observation that detectable thyroid antibodies
were associated with a higher median preconception
TSH concentration is consistent with previous reports
that women with thyroid antibodies generally exhibit
higher serum TSH levels before and during pregnancy
[2,15,16]. However, these previous studies included
infertile women or women with pre-existing hypothyr-
oidism, conditions which themselves may have altered
thyroid function and pregnancy outcomes. Unlike the
previous studies, our subjects were not infertile and did
not have a previous diagnosis of hypothyroidism.
Our data suggest that the higher TSH concentrations
observed before and during early pregnancy in women
with thyroid antibodies more likely reflects a possible
subclinical pathology. Even with TSH and FT4 levels
within the “normal” range prior to pregnancy, antibody
positive women may have compromised basal thyroid
function. Among women with thyroid antibodies, the
absolute change in TSH with pregnancy was highly vari-
able, implying that a pre-pregnancy TSH value will not
necessarily predict pregnancy thyroid function among
women with antibodies. Pregnancy may serve as a pro-
vocative test of thyroid status among women with anti-
bodies. Unfortunately, for a subgroup, pregnancy may
lead to thyroid dysfunction, placing them at increased
risk for poor pregnancy outcomes including miscarriage
[15,17].
Our data raise questions regarding current thyroid
screening guidelines, which recommend targeted screen-
ing for thyroid disease in high-risk groups during preg-
nancy [18,19]. The majority of women typically do not
begin prenatal care before 8-10 weeks gestation, when
TSH concentrations already have decreased significantly
from preconception levels. Our data suggest that TSH
concentrations start declining after 6 weeks gestation.
Consequently, patients with subclinical thyroid dysfunc-
tion (as determined by elevated pre-pregnancy TSH
values) may fail to be detected by thyroid screening in
the first trimester. This discrepancy may explain the
lack of a consistent association between pregnancy TSH
values and miscarriage [20] despite an observed associa-
tion between thyroid antibodies and miscarriage [21].
In our study cohort, eight (13%) subjects had TSH
levels more than 2 SD above the mean before concep-
tion. Four of the eight (50%) had a normal TSH concen-
tration in early pregnancy (< 2.5 mIU/liter) and would
have screened normal if only tested antenatally. If pre-
conception testing is the more accurate measure of
maternal thyroid function, screening during pregnancy
may yield falsely reassuring results unless thyroid anti-
body status is considered in the evaluation and treat-
ment algorithm. Conversely, if testing during early
pregnancy best reflects true maternal thyroid function,
preconception screening may result in over-diagnosis of
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hypothyroidism and unnecessary treatment in a signifi-
cant proportion of women. Conclusions from this obser-
vation are limited due our small sample size.
Our study is the first to examine longitudinal pericon-
ceptional changes in thyroid hormone levels in a normal
fertile population. This study design allows us to under-
stand the relationship between pre-pregnancy and preg-
nancy thyroid function within an individual. Knowledge
gained from such studies can be used to determine the
most appropriate timing for thyroid screening among
reproductively competent women. The subjects enrolled
had no prior history of thyroid disease and exhibited
normal fecundity by having conceived within six men-
strual cycles. Moreover, there were no differences in the
median ages of subgroups with and without thyroid
antibodies and those having a preconceptional TSH con-
centration greater than 3.0 mIU/L.
The proportion of women in our cohort having
detectable thyroid antibodies (16/60, 27%) was some-
what higher than has been observed in larger popula-
tions (14-18%), but the difference is not statistically
significant (p = 0.07) [11]. Our study used an assay with
a lower antibody detection level (1 U/ml) than used in
some previous studies of thyroid autoimmunity and
pregnancy [9,17]. It is possible that the periconceptional
changes in TSH may be more pronounced in women
with higher thyroid antibody levels and in populations
where antibody positivity is defined by a higher thresh-
old, potentially increasing the likelihood for a negative
reproductive outcome.
Our study has several limitations. The cohort of sub-
jects was relatively small, including only 60 women.
More importantly, the patterns of periconceptional
change in measures of thyroid function were defined by
sampling at only two time points in each individual.
Nonetheless, our observations indicate the need for lar-
ger and more sophisticated longitudinal studies with
serial testing immediately before conception and at fre-
quent intervals during early pregnancy, ideally beginning
at four weeks gestation, to better define the patterns of
periconceptional change in measures of thyroid function
and determine their clinical relevance. In addition, our
sample was limited to women between the ages of 30-42
years and therefore may not accurately represent the lar-
ger population, but the narrower age range of the sub-
jects in our study improved our ability to examine the
impact of thyroid antibodies on periconceptional
changes in thyroid function.
Conclusions
The periconception interval encompasses dynamic
changes in thyroid function, as reflected by a progressive
decrease in serum TSH concentrations. Moreover, the
patterns of change appear to be highly variable among
women with thyroid antibodies. Current guidelines for
screening thyroid function only during early pregnancy
may fail to identify all women who might benefit from
early intervention.
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